

PerCP/Cyanine5.5 anti-mouse NK-1.1 Antibody

Catalog# / Size	108727 / 25 µg 108728 / 100 µg
Clone	PK136
Regulatory Status	RUO
Other Names	NKR-P1C, NKR-P1B, Ly-55, CD161, CD161b, CD161c
Isotype	Mouse IgG2a, κ
Description	NK-1.1 surface antigen, also known as CD161b/CD161c and Ly-55, is encoded by the NKR-P1B/NKR-P1C gene. It is expressed on NK cells and NK-T cells in some mouse strains, including C57BL/6, FVB/N, and NZB, but not AKR, BALB/c, CBA/J, C3H, DBA/1, DBA/2, NOD, SJL, and 129. Expression of NKR-P1C antigen has been correlated with lysis of tumor cells <i>in vitro</i> and rejection of bone marrow allografts <i>in vivo</i> . NK-1.1 has also been shown to play a role in NK cell activation, IFN-γ production, and cytotoxic granule release. NK-1.1 and DX5 are commonly used as mouse NK cell markers.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Mouse
Immunogen	NK-1 ⁺ cells from mouse spleen and bone marrow
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is = 1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. * PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunoprecipitation ^{1,2} , complement-dependent cytotoxicity ³ , <i>in vivo</i> depletion ^{4,5,9,10} , mediation of <i>in vitro</i> redirected lysis ⁶ , blocking of NK cell function ⁷ , induction of proliferation ⁸ , immunohistochemical staining of frozen sections ¹¹ , immunofluorescence microscopy ¹¹ , and spatial biology (IBEX) ^{16,17} . The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).
Additional Product Notes	BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References	1. Carlyle JR, <i>et al.</i> 1999. <i>J. Immunol.</i> 162:5917. (IP) 2. Sentman CL, <i>et al.</i> 1989. <i>Hybridoma</i> 8:605. (IP) 3. Koo GC, <i>et al.</i> 1984. <i>Hybridoma</i> 3:301. (Cyt)
(PubMed link indicates BioLegend citation)	

4. Sentman CL, *et al.* 1989. *J. Immunol.* 142:1847. (Deplete)
5. Koo GC, *et al.* 1986. *J. Immunol.* 137:3742. (Deplete)
6. Karlhofer FM, *et al.* 1991. *J. Immunol.* 146:3662.
7. Kung SK, *et al.* 1999. *J. Immunol.* 162:5876. (Block)
8. Reichlin A, *et al.* 1998. *Immunol. Cell Biol.* 76:143.
9. Drobyski W, *et al.* 1996. *Blood* 87:5355. (Deplete)
10. Andoniou CE, *et al.* 2005. *Nat. Immunol.* 6:1011. (Deplete)
11. Kanwar JR, *et al.* 2001. *J. Natl. Cancer Inst.* 93:1541. (IHC, IF)
12. Kroemer A, *et al.* 2008. *J. Immunol.* 180:7818. [PubMed](#)
13. Kim JY, *et al.* 2009. *Exp Mol Med.* 30:288. [PubMed](#)
14. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
15. Lee H, *et al.* 2014. *Invest Ophthalmol Vis Sci.* 55:2885. [PubMed](#)
16. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
17. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Minute L, *et al.* 2020. *J Immunother Cancer.* 8:. [PubMed](#)
2. Kobayashi T, *et al.* 2019. *Cell.* 176:982. [PubMed](#)
3. Liang S, *et al.* 2022. *Acta Pharm Sin B.* 12:2494. [PubMed](#)
4. Okuniewska M, *et al.* 2021. *Cell Reports.* 36(2):109368. [PubMed](#)
5. Jtte BB, *et al.* 2021. *iScience.* 24(8):102833. [PubMed](#)
6. Wang C, *et al.* 2021. *Cell Rep.* 37:110021. [PubMed](#)
7. Montel-Hagen A, *et al.* 2020. *Cell Rep.* 33:108320. [PubMed](#)
8. Chen L, *et al.* 2020. *J Exp Med.* 217:00:00. [PubMed](#)
9. Trotta E, *et al.* 2018. *Nat Med.* 24:1005. [PubMed](#)
10. Terashima Y, *et al.* 2020. *Nat Commun.* 11:609. [PubMed](#)
11. Dane EL, *et al.* 2022. *Nat Mater.* 21:710. [PubMed](#)
12. Zhang L, *et al.* 2021. *Methods Mol Biol.* 2388:175. [PubMed](#)
13. Park D, *et al.* 2020. *Cancer Res.* 80:4172. [PubMed](#)
14. He Y, *et al.* 2021. *Cell Metabolism.* 33(5):988-1000.e7. [PubMed](#)
15. Abdul Pari AA, *et al.* 2020. *Cancer Res.* 80:2586. [PubMed](#)
16. Kooreman NG *et al.* 2018. *Cell stem cell.* 22(4):501-513. [PubMed](#)
17. Lee DH, *et al.* 2019. *PLoS One.* 14:e0215727. [PubMed](#)
18. Peauroi EM, *et al.* 2022. *iScience.* 25:105510. [PubMed](#)
19. Bergin SM, *et al.* 2021. *Brain Behav Immun.* 95:477. [PubMed](#)
20. Momin N, *et al.* 2022. *Nat Commun.* 13:109. [PubMed](#)
21. Gironi M, *et al.* 2021. *Blood Adv.* 5:2817. [PubMed](#)
22. Liyanage S, *et al.* 2016. *Exp Eye Res.* 151:160-70. [PubMed](#)
23. Bates PD, *et al.* 2021. *Front Immunol.* 12:668307. [PubMed](#)
24. Monaghan KL, *et al.* 2020. *J Vis Exp.* . [PubMed](#)
25. Georgoudaki A, *et al.* 2016. *Cell Rep.* 15: 2000-2011. [PubMed](#)
26. Matsumura T, *et al.* 2022. *Nat Commun.* 13:7064. [PubMed](#)
27. Sakamoto K, *et al.* 2021. *Immunity.* 54:2321. [PubMed](#)
28. Robertson TF, *et al.* 2021. *J Cell Biol.* 220:. [PubMed](#)
29. Ko HJ, *et al.* 2020. *Front Immunol.* 1897:11. [PubMed](#)
30. Bennett FC, *et al.* 2018. *Neuron.* 98:1170. [PubMed](#)
31. McGinty JW, *et al.* 2020. *Immunity.* 52(3):528-541. [PubMed](#)
32. Dallari S, *et al.* 2021. *Cell Host Microbe.* 29(6):1014-1029.e8. [PubMed](#)
33. Rosato PC, *et al.* 2019. *Nat Commun.* 10:567. [PubMed](#)
34. Kiss M, *et al.* 2020. *Cancer Immunol Res.* 9:309. [PubMed](#)
35. Gardner P, *et al.* 2017. *Sci Rep.* 7:40830. [PubMed](#)
36. Yoshida H, *et al.* 2019. *Cell.* 176:897. [PubMed](#)
37. Hildreth AD, *et al.* 2020. *STAR Protoc.* 1:100113. [PubMed](#)
38. Teng F, *et al.* 2021. *Cell Rep.* 37:110051. [PubMed](#)
39. Sakamoto K, *et al.* 2022. *STAR Protoc.* 3:101052. [PubMed](#)
40. Spiljar M, *et al.* 2021. *Cell Metab.* 33:2231. [PubMed](#)
41. Gawish R, *et al.* 2022. *Elife.* 11:. [PubMed](#)
42. Nabekura T, *et al.* 2020. *Immunity.* 96:52. [PubMed](#)
43. Tian L, *et al.* 2012. *J Autoimmun.* 38:39. [PubMed](#)
44. Thomson CA, *et al.* 2018. *J Immunol.* 201:215. [PubMed](#)
45. Song X, *et al.* 2022. *Transl Oncol.* 15:101306. [PubMed](#)

RRID

AB_2132706 (BioLegend Cat. No. 108727)
 AB_2132705 (BioLegend Cat. No. 108728)

Antigen Details

Structure	NKR-P1 gene family
Distribution	NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)
Function	NK cell activation, IFN- γ production, cytotoxic granule release
Cell Type	NK cells, NKT cells
Biology Area	Immunology, Innate Immunity

Antigen References

1. Lanier LL. 1997. *Immunity* 6:371.
2. Yokoyama WM, et al. 1993. *Ann. Rev. Immunol.* 11:613.
3. Koo GC, et al. 1986. *J. Immunol.* 137:3742.
4. Giorda R, et al. 1991. *J. Immunol.* 147:1701.

Gene ID

[17059](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse NK-1.1, Biotin anti-mouse NK-1.1, FITC anti-mouse NK-1.1, PE anti-mouse NK-1.1, Purified anti-mouse NK-1.1, PE/Cyanine7 anti-mouse NK-1.1, PE/Cyanine5 anti-mouse NK-1.1, Alexa Fluor® 488 anti-mouse NK-1.1, Alexa Fluor® 647 anti-mouse NK-1.1, Pacific Blue™ anti-mouse NK-1.1, Brilliant Violet 711™ anti-mouse NK-1.1, APC/Cyanine7 anti-mouse NK-1.1, PerCP anti-mouse NK-1.1, PerCP/Cyanine5.5 anti-mouse NK-1.1, Alexa Fluor® 700 anti-mouse NK-1.1, Brilliant Violet 421™ anti-mouse NK-1.1, Brilliant Violet 570™ anti-mouse NK-1.1, Brilliant Violet 650™ anti-mouse NK-1.1, Brilliant Violet 510™ anti-mouse NK-1.1, Brilliant Violet 605™ anti-mouse NK-1.1, Purified anti-mouse NK-1.1 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse NK-1.1, Brilliant Violet 785™ anti-mouse NK-1.1, APC/Fire™ 750 anti-mouse NK-1.1, TotalSeq™-A0118 anti-mouse NK-1.1, Ultra-LEAF™ Purified anti-mouse NK-1.1, TotalSeq™-B0118 anti-mouse NK-1.1, TotalSeq™-C0118 anti-mouse NK-1.1, PE/Fire™ 810 anti-mouse NK-1.1

Product Data



C57BL/6 mouse splenocytes were stained with CD49b (pan-NK cells) APC and NK1.1 (clone PK136) PerCP/Cyanine5.5 (left), or mouse IgG2a, κ isotype control (right).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587